ACM
IONS icon

Atika Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Atika Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-47,488
Closed -$3.76M – 78
2025
Q4 		$3.76M Buy
47,488
+25,988
+121% +$1.96M 0.4% 67
2025
Q3 		$1.41M Buy
+21,500
New +$1.05M 0.11% 81
2016
Q1 		– Sell
-38,000
Closed -$2.35M – 51
2015
Q4 		$2.35M Buy
+38,000
New +$2.05M 1.21% 32

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's IONS Position: Q1 2026 in Review

Atika Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q1 2026, closing a stake of 47,488 shares — an estimated $3.76M sold.

Atika Capital Management first reported a position in IONS in Q4 2015 and held it in 3 quarters. The position peaked at $3.76M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Atika Capital Management reported no remaining Ionis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Atika Capital Management sold 47,488 Ionis Pharmaceuticals shares in Q1 2026, an estimated $3.76M.
  • Atika Capital Management first reported a position in Ionis Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Atika Capital Management's Ionis Pharmaceuticals position peaked at $3.76M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.